Format

Send to

Choose Destination
Euro Surveill. 2018 May;23(21). doi: 10.2807/1560-7917.ES.2018.23.21.1800264.

Multidrug-resistant Neisseria gonorrhoeae failing treatment with ceftriaxone and doxycycline in France, November 2017.

Author information

1
French National Reference Center for bacterial STI, Associated laboratory for gonococci, APHP, Paris, France.
2
Infectious Agents Department, Saint Louis Hospital, APHP, Paris, France.
3
Dermatology Department, CeGGID (Free Information Screening and Diagnostics Centers), Saint Louis Hospital, APHP, Paris, France.
4
Paris Diderot University, IAME, UMR 1137, Sorbonne Paris Cité, Paris, France.
5
University of Bordeaux, USC EA 3671 Mycoplasmal and chlamydial infections in humans; Centre Hospitalier Universitaire de Bordeaux, French National Reference Center for bacterial STIs, Bordeaux, France.
6
Santé Publique France, French National Public Health Agency, Saint-Maurice, France.
7
WHO Collaborating Centre for Gonorrhoea and Other STIs, National Reference Laboratory for STIs, Department of Laboratory Medicine, Faculty of Medicine and Health, Ӧrebro University, Ӧrebro, Sweden.

Abstract

We report a multidrug-resistant Neisseria gonorrhoeae urogenital and pharyngeal infection with ceftriaxone resistance and intermediate resistance to azithromycin in a heterosexual woman in her 20s in France. Treatment with ceftriaxone plus doxycycline failed for the pharyngeal localisation. Whole-genome sequencing of isolate F90 identified MLST1903, NG-MAST ST3435, NG-STAR233, and relevant resistance determinants. F90 showed phenotypic and genotypic similarities to an internationally spreading multidrug-resistant and ceftriaxone-resistant clone detected in Japan and subsequently in Australia, Canada and Denmark.

KEYWORDS:

antimicrobial resistance; antimicrobial treatment; diagnosis; gonorrhoea; treatment failure

Supplemental Content

Full text links

Icon for Ingenta plc Icon for PubMed Central
Loading ...
Support Center